Reviva Pharmaceuticals (US:RVPH)2025-11-13 21:19Financial Performance - The company reported a net loss of approximately $4.0 million, or $0.06 per share, for Q3 2025, a decrease from a net loss of approximately $8.4 million, or $0.25 per share, in Q3 2024[4] - Cash and cash equivalents totaled approximately $13.2 million as of September 30, 2025, compared to approximately $13.5 million as of December 31, 2024[6] - The company reported a total operating expense of $4.0 million for Q3 2025, down from $8.5 million in Q3 2024[13] Fundraising Activities - The company completed a public equity offering raising gross proceeds of $9.0 million before deducting fees and expenses[5] Drug Development and Research - A positive dataset from the Phase 3 RECOVER study showed robust efficacy for brilaroxazine in schizophrenia, with a PANSS total score improvement of -18.1[3] - The company plans to submit a New Drug Application (NDA) for brilaroxazine for schizophrenia in Q2 2026, following a pre-NDA meeting with the FDA in Q4 2025[2] - The Phase 3 RECOVER study included 446 patients, demonstrating favorable long-term safety and tolerability for brilaroxazine[3] - The company has plans for an investigational new drug application (IND) submission for a liposomal-gel formulation of brilaroxazine in psoriasis expected by H2-2026[5] Intellectual Property - The European Patent Office granted a patent for brilaroxazine for treating pulmonary fibrosis, adding to existing protections in key markets[3] - The company aims to expand its patent portfolio and pursue partnership opportunities for pipeline development[5]